NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Hope4patients. Exactly. FUD and manipulators trying to get people to think $10/sh. That would be a similar valuation to Kite Pharma (Car-T) sold to Gilead for $12B in 2017 with only a Phase 2 trial for relapsed or refractory large B-cell lymphoma (LBCL). The fallacy in the comparison.

Kite translation:
- “relapsed or refractory” means a realizable revenue that is a % of a % of a %.
- LBCL is a subset of non-Hodgkin lymphoma (NHL), which is already a subset of Lymphomas
- Relapse refers to treating only recurrent NHL, not newly diagnosed
- Refractory means not SOC for LBCL, but only as a 2nd line of treatment when patient is not responsive to initial treatment
- Car-T is known for high toxicity risks

- Newly diagnosed LBCL in USA each year – 18K
- 30-40% LBCL will need a 2nd line of treatment – 5K to 7K
- Calculation (per Bard, Yescarta has maybe 50% of LBCL) - ~3K patients

Compare that to NWBO’s DCVax-L for brain tumors
- Applicable for the entire brain tumor type
- MAA to MHRA is for approval to treat all GBM, malignant gliomas, and AA
- 1st line of treatment
- Efficacy, non-toxic, immune memory
- Competition: minimal because above and tech platform ideal for combination therapies
- Off label for early stage and benign brain: ideal as a prophylactic to prevent progression

- Newly Diagnosed Primary Brain Tumors in the USA in 2023 – 94K
- GBM and malignant is 28% - 26K patients
- Benign is 72% - Off label means a % of 68K patients, but anticipate eventual label expansion and SOC
https://braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/

NWBO is poised to take the entire brain tumor market. I believe the key to investing in a unicorn company is to hold it long term, ignore the noise and remain disciplined. Years from now, the key will have been the time invested, not timing. Even 20X increase from here will be nothing. The real gains will be the step ladder jumps when new revelations of revenue potential for the DCVax technology platform become apparent, year after year.